Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Merck (NYSE:MRK) is scheduled to announce Q4 earnings results on Tuesday, February 4th, before market open. Truist Securities ...

Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...

Merck on Friday said the recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use covers the 21-valent conjugate vaccine for immunization for the prevention ...

Disclosed in the latest SEC filing, a significant insider purchase on January 29, involves Chirfi Guindo, Chief Marketing Officer at Merck & Co MRK.

Merck, a leading science and technology company, today launched a beta version of M-Trust, a secure cyber-physical trust platform, created to help solve the growing issues of product safety ...